The company announces that a Private Placement has been successfully placed, raising gross proceeds of NOK 230 million by allocating 5,750,000 shares at a subscription price of NOK 40.00 per Offer Share.
The Private Placement received strong interest from existing shareholders and new investors. The net proceeds from the Private Placement will i.a. be used to conduct a Phase IIa clinical study combining Vaccibody’s product candidate VB10.16 with Roche’s checkpoint inhibitor Atezolizumab, prepare for expansion cohorts in Vaccibody’s VB10.NEO cancer neoantigen programme and initiation of two expansion cohorts, as well as for general corporate purposes.
Following registration of the share capital increase pertaining to the Private Placement, the Company will have a share capital of NOK 2,711,494, divided into 54,229,880 shares, each with a nominal value of NOK 0.05. In addition, there are 4,128,369 outstanding warrants issued to key personnel.